Joseph E. Gilliam Sells 3,328 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Glaukos Price Performance

Shares of GKOS stock traded down $2.52 on Monday, hitting $148.36. 446,681 shares of the stock traded hands, compared to its average volume of 576,100. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a 52 week low of $74.75 and a 52 week high of $151.92. The firm has a 50 day simple moving average of $138.42 and a two-hundred day simple moving average of $128.46. The firm has a market cap of $8.18 billion, a price-to-earnings ratio of -49.13 and a beta of 1.03.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. The business had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business’s quarterly revenue was up 23.9% on a year-over-year basis. During the same period last year, the firm earned ($0.50) earnings per share. As a group, equities research analysts predict that Glaukos Co. will post -1.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Values First Advisors Inc. bought a new stake in shares of Glaukos during the third quarter valued at approximately $25,000. Harvest Fund Management Co. Ltd boosted its position in shares of Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 860 shares during the last quarter. KBC Group NV grew its stake in Glaukos by 16.2% during the third quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock valued at $188,000 after acquiring an additional 201 shares in the last quarter. Brighton Jones LLC bought a new stake in Glaukos in the 2nd quarter valued at $208,000. Finally, EWA LLC purchased a new stake in Glaukos in the 3rd quarter worth $209,000. 99.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GKOS shares. Stephens upgraded shares of Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. Truist Financial increased their price target on Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. lifted their price objective on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Piper Sandler set a $140.00 target price on Glaukos in a report on Thursday, October 17th. Finally, Wells Fargo & Company boosted their price target on Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $145.92.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.